Zacks Investment Research cut shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.
According to Zacks, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey. “
Several other research firms have also commented on EGRX. Cantor Fitzgerald set a $80.00 price target on shares of Eagle Pharmaceuticals and gave the company a buy rating in a research report on Tuesday, October 30th. ValuEngine cut shares of Eagle Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, October 31st. Piper Jaffray Companies cut shares of Eagle Pharmaceuticals from an overweight rating to a neutral rating and dropped their price objective for the stock from $82.00 to $54.00 in a research note on Wednesday, October 31st. Royal Bank of Canada set a $64.00 target price on Eagle Pharmaceuticals and gave the company a buy rating in a research report on Friday, November 2nd. Finally, Mizuho decreased their target price on Eagle Pharmaceuticals to $52.00 and set a neutral rating on the stock in a research report on Wednesday, November 7th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus target price of $69.33.
EGRX stock traded up $0.31 during mid-day trading on Tuesday, reaching $41.72. 463 shares of the stock traded hands, compared to its average volume of 169,421. The company has a quick ratio of 5.38, a current ratio of 5.59 and a debt-to-equity ratio of 0.20. Eagle Pharmaceuticals has a one year low of $36.03 and a one year high of $85.66. The stock has a market capitalization of $617.42 million, a price-to-earnings ratio of 12.22 and a beta of 1.69.
In related news, CEO Scott Tarriff sold 30,085 shares of the business’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $41.54, for a total transaction of $1,249,730.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 28.20% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. WINTON GROUP Ltd acquired a new position in shares of Eagle Pharmaceuticals in the fourth quarter valued at approximately $9,552,000. ClariVest Asset Management LLC grew its holdings in Eagle Pharmaceuticals by 35.1% during the fourth quarter. ClariVest Asset Management LLC now owns 53,806 shares of the specialty pharmaceutical company’s stock worth $2,167,000 after acquiring an additional 13,971 shares during the period. LS Investment Advisors LLC grew its holdings in Eagle Pharmaceuticals by 97.9% during the fourth quarter. LS Investment Advisors LLC now owns 2,157 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 1,067 shares during the period. Algert Global LLC grew its holdings in Eagle Pharmaceuticals by 254.5% in the fourth quarter. Algert Global LLC now owns 21,779 shares of the specialty pharmaceutical company’s stock valued at $877,000 after purchasing an additional 15,636 shares during the last quarter. Finally, Chartwell Investment Partners LLC grew its holdings in Eagle Pharmaceuticals by 38.9% in the fourth quarter. Chartwell Investment Partners LLC now owns 216,187 shares of the specialty pharmaceutical company’s stock valued at $8,710,000 after purchasing an additional 60,578 shares during the last quarter.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Further Reading: How does inflation affect different investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.